Largactil

Chlorpromazine, the active ingredient in Largactil, is a phenothiazine presented as an oral tablet for oral use. It is employed to manage psychotic disorders and severe nausea in adult patients. The medication works by blocking dopamine receptors, which helps to reduce hallucinations, delusions, and agitation. It may also be used in the management of bipolar manic episodes.

GNH USA supplies Largactil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics for global health partners.

Chlorpromazine is a typical antipsychotic that acts on dopamine pathways to treat several psychiatric and gastrointestinal conditions. - Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations and thought disorder. - Acute psychotic episodes: alleviates severe agitation and hallucinations during sudden psychotic crises. - Manic phases of bipolar disorder: helps control elevated mood, hyperactivity and irritability. - Severe nausea and vomiting: controls refractory emesis when other anti‑emetics are ineffective.

Chlorpromazine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Dry mouth: reduced salivation leading to discomfort. - Constipation: slowed gastrointestinal motility. - Weight gain: increase in body weight over time.

Serious or Rare Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor, or involuntary movements. - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle breakdown. - Tardive dyskinesia: persistent involuntary facial or limb movements after long‑term use.

When prescribing chlorpromazine, clinicians should consider several precautionary measures to ensure patient safety. - Assess cardiac history: monitor for QT prolongation and arrhythmias. - Evaluate liver function: dose adjustment may be needed in hepatic impairment. - Monitor for signs of hypotension: especially after the first doses. - Caution in elderly patients: increased sensitivity to sedative and anticholinergic effects. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Chlorpromazine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension or serotonin syndrome. - CNS depressants (e.g., benzodiazepines, opioids): may cause profound sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: additive dry mouth, constipation, and urinary retention. - Antihypertensive agents: enhanced hypotensive effect. - CYP2D6 substrates (e.g., metoprolol): chlorpromazine may inhibit metabolism, increasing plasma levels.